Cargando…

Histone deacetylase inhibition by Entinostat for the prevention of electrical and structural remodeling in heart failure

BACKGROUND: The development of heart failure is accompanied by complex changes in cardiac electrophysiology and functional properties of cardiomyocytes and fibroblasts. Histone deacetylase (HDAC) inhibitors hold great promise for the pharmaceutical therapy of several malignant diseases. Here, we des...

Descripción completa

Detalles Bibliográficos
Autores principales: Freundt, Johanna K., Frommeyer, Gerrit, Spieker, Tilmann, Wötzel, Fabian, Grotthoff, Jochen Schulze, Stypmann, Jörg, Hempel, Georg, Schäfers, Michael, Jacobs, Andreas H., Eckardt, Lars, Lange, Philipp S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6404297/
https://www.ncbi.nlm.nih.gov/pubmed/30841920
http://dx.doi.org/10.1186/s40360-019-0294-x
_version_ 1783400846489288704
author Freundt, Johanna K.
Frommeyer, Gerrit
Spieker, Tilmann
Wötzel, Fabian
Grotthoff, Jochen Schulze
Stypmann, Jörg
Hempel, Georg
Schäfers, Michael
Jacobs, Andreas H.
Eckardt, Lars
Lange, Philipp S.
author_facet Freundt, Johanna K.
Frommeyer, Gerrit
Spieker, Tilmann
Wötzel, Fabian
Grotthoff, Jochen Schulze
Stypmann, Jörg
Hempel, Georg
Schäfers, Michael
Jacobs, Andreas H.
Eckardt, Lars
Lange, Philipp S.
author_sort Freundt, Johanna K.
collection PubMed
description BACKGROUND: The development of heart failure is accompanied by complex changes in cardiac electrophysiology and functional properties of cardiomyocytes and fibroblasts. Histone deacetylase (HDAC) inhibitors hold great promise for the pharmaceutical therapy of several malignant diseases. Here, we describe novel effects of the class I HDAC inhibitor Entinostat on electrical and structural remodeling in an in vivo model of pacing induced heart failure. METHODS: Rabbits were implanted a pacemaker system, subjected to rapid ventricular pacing and treated with Entinostat or placebo, respectively. Following stimulation, rabbit hearts were explanted and subsequently subjected to electrophysiological studies and further immunohistological analyses of left ventricles. RESULTS: In vivo, rapid ventricular stimulation caused a significant prolongation of monophasic action potential duration compared to sham hearts (from 173 ± 26 ms to 250 ± 41 ms; cycle length 900 ms; p < 0.05) and an increased incidence of Early afterdepolarisations (+ 150%), while treatment with Entinostat in failing hearts could partially prevent this effect (from 250 ± 41 ms to 170 ± 53 ms, p < 0.05; reduction in EAD by 50%). Entinostat treatment partially restored KCNH2 and Cav1.3 gene expressions in failing hearts, and inhibited the development of cardiac fibrosis in vivo. CONCLUSION: In a rabbit model of heart failure, Entinostat diminishes heart failure related prolongation of repolarization and partially restores KCNH2 and Cav1.3 expression. In addition, Entinostat exerts antifibrotic properties both in vitro and in vivo. Thus, Entinostat might be an interesting candidate for the pharmaceutical therapy of heart failure directed against structural and electrical remodeling. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s40360-019-0294-x) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6404297
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-64042972019-03-18 Histone deacetylase inhibition by Entinostat for the prevention of electrical and structural remodeling in heart failure Freundt, Johanna K. Frommeyer, Gerrit Spieker, Tilmann Wötzel, Fabian Grotthoff, Jochen Schulze Stypmann, Jörg Hempel, Georg Schäfers, Michael Jacobs, Andreas H. Eckardt, Lars Lange, Philipp S. BMC Pharmacol Toxicol Research Article BACKGROUND: The development of heart failure is accompanied by complex changes in cardiac electrophysiology and functional properties of cardiomyocytes and fibroblasts. Histone deacetylase (HDAC) inhibitors hold great promise for the pharmaceutical therapy of several malignant diseases. Here, we describe novel effects of the class I HDAC inhibitor Entinostat on electrical and structural remodeling in an in vivo model of pacing induced heart failure. METHODS: Rabbits were implanted a pacemaker system, subjected to rapid ventricular pacing and treated with Entinostat or placebo, respectively. Following stimulation, rabbit hearts were explanted and subsequently subjected to electrophysiological studies and further immunohistological analyses of left ventricles. RESULTS: In vivo, rapid ventricular stimulation caused a significant prolongation of monophasic action potential duration compared to sham hearts (from 173 ± 26 ms to 250 ± 41 ms; cycle length 900 ms; p < 0.05) and an increased incidence of Early afterdepolarisations (+ 150%), while treatment with Entinostat in failing hearts could partially prevent this effect (from 250 ± 41 ms to 170 ± 53 ms, p < 0.05; reduction in EAD by 50%). Entinostat treatment partially restored KCNH2 and Cav1.3 gene expressions in failing hearts, and inhibited the development of cardiac fibrosis in vivo. CONCLUSION: In a rabbit model of heart failure, Entinostat diminishes heart failure related prolongation of repolarization and partially restores KCNH2 and Cav1.3 expression. In addition, Entinostat exerts antifibrotic properties both in vitro and in vivo. Thus, Entinostat might be an interesting candidate for the pharmaceutical therapy of heart failure directed against structural and electrical remodeling. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s40360-019-0294-x) contains supplementary material, which is available to authorized users. BioMed Central 2019-03-06 /pmc/articles/PMC6404297/ /pubmed/30841920 http://dx.doi.org/10.1186/s40360-019-0294-x Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Freundt, Johanna K.
Frommeyer, Gerrit
Spieker, Tilmann
Wötzel, Fabian
Grotthoff, Jochen Schulze
Stypmann, Jörg
Hempel, Georg
Schäfers, Michael
Jacobs, Andreas H.
Eckardt, Lars
Lange, Philipp S.
Histone deacetylase inhibition by Entinostat for the prevention of electrical and structural remodeling in heart failure
title Histone deacetylase inhibition by Entinostat for the prevention of electrical and structural remodeling in heart failure
title_full Histone deacetylase inhibition by Entinostat for the prevention of electrical and structural remodeling in heart failure
title_fullStr Histone deacetylase inhibition by Entinostat for the prevention of electrical and structural remodeling in heart failure
title_full_unstemmed Histone deacetylase inhibition by Entinostat for the prevention of electrical and structural remodeling in heart failure
title_short Histone deacetylase inhibition by Entinostat for the prevention of electrical and structural remodeling in heart failure
title_sort histone deacetylase inhibition by entinostat for the prevention of electrical and structural remodeling in heart failure
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6404297/
https://www.ncbi.nlm.nih.gov/pubmed/30841920
http://dx.doi.org/10.1186/s40360-019-0294-x
work_keys_str_mv AT freundtjohannak histonedeacetylaseinhibitionbyentinostatforthepreventionofelectricalandstructuralremodelinginheartfailure
AT frommeyergerrit histonedeacetylaseinhibitionbyentinostatforthepreventionofelectricalandstructuralremodelinginheartfailure
AT spiekertilmann histonedeacetylaseinhibitionbyentinostatforthepreventionofelectricalandstructuralremodelinginheartfailure
AT wotzelfabian histonedeacetylaseinhibitionbyentinostatforthepreventionofelectricalandstructuralremodelinginheartfailure
AT grotthoffjochenschulze histonedeacetylaseinhibitionbyentinostatforthepreventionofelectricalandstructuralremodelinginheartfailure
AT stypmannjorg histonedeacetylaseinhibitionbyentinostatforthepreventionofelectricalandstructuralremodelinginheartfailure
AT hempelgeorg histonedeacetylaseinhibitionbyentinostatforthepreventionofelectricalandstructuralremodelinginheartfailure
AT schafersmichael histonedeacetylaseinhibitionbyentinostatforthepreventionofelectricalandstructuralremodelinginheartfailure
AT jacobsandreash histonedeacetylaseinhibitionbyentinostatforthepreventionofelectricalandstructuralremodelinginheartfailure
AT eckardtlars histonedeacetylaseinhibitionbyentinostatforthepreventionofelectricalandstructuralremodelinginheartfailure
AT langephilipps histonedeacetylaseinhibitionbyentinostatforthepreventionofelectricalandstructuralremodelinginheartfailure